The Latest Cardiac and Vascular News
LATHAM, N.Y.–(BUSINESS WIRE)–AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality of life, today announced that it has entered into a settlement agreement with Becton, Dickinson and Company (“BD”) […]
FRANKLIN LAKES, N.J., June 1, 2018 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today appointed John A. DeFord as executive vice president and chief technology officer. DeFord, 56, will report to Tom Polen, president of BD, and will be responsible for leading […]
NEW YORK, April 2, 2018 /PRNewswire/ — C.R. Bard, Inc. has been ordered to pay $3.6 million to a Georgia woman who suffered serious complications after the company’s G2 inferior vena cava (IVC) filter fractured inside her body. The case was the first to go to trial in the U.S. District Court, District of Arizona, where more than […]
FRANKLIN LAKES, N.J., Dec. 22, 2017 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, issued the following statement regarding today’s clearance by the U.S. Federal Trade Commission (FTC) for BD to acquire C. R. Bard (NYSE: BCR), contingent on the divestitures of BD’s soft tissue core […]
Shares of Merit Medical Systems have jumped more than 9 percent this morning after the company announced it plunked down $100 million for two product lines belonging to Becton, Dickinson and Company (BD). BD is selling the assets in connection with its acquisition of C.R. Bard Inc.(Bard). Merit will acquire soft tissue core needle biopsy products currently […]
FRANKLIN LAKES, N.J., Oct. 18, 2017 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, issued the following statement regarding today’s clearance by the European Commission for BD to acquire C.R. Bard (NYSE: BCR), contingent on BD divesting its soft tissue core needle biopsy product line: “We […]
